Protagonist Therapeutics, Inc.
PTGX
Clasificación en acciones
#2249
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Precio por acción
$138.50
Última sincronización: 2026-10-20
Capitalización bursátil
$8.96B
Cambio (1 día)
3.02%
Cambio (1 año)
84.67%
País
US
Comercio Protagonist Therapeutics, Inc. (PTGX)
Categoría
Healthcare
Número de acciones en circulación de Protagonist Therapeutics, Inc. (PTGX)
Número de acciones en circulación al June 2026: 65.94M
Según los últimos informes financieros y el precio de las acciones de Protagonist Therapeutics, Inc., el número actual de acciones en circulación es 65.94M. Al final de December 2023, la empresa tenía 56.76M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Protagonist Therapeutics, Inc. (PTGX) desde 2014 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 65.94M | 7.10% |
| 2024 | 61.57M | 8.46% |
| 2023 | 56.76M | 15.74% |
| 2022 | 49.04M | 5.87% |
| 2021 | 46.32M | 34.67% |
| 2020 | 34.40M | 32.84% |
| 2019 | 25.89M | 15.78% |
| 2018 | 22.36M | 26.39% |
| 2017 | 17.69M | 172.15% |
| 2016 | 6.50M | 10.48% |
| 2015 | 5.88M | 0.00% |
| 2014 | 5.88M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 285.07% |
US
|
|
| 396.00M | 500.58% |
US
|
|
| 478.91M | 626.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -5.69% |
NL
|
